382 related articles for article (PubMed ID: 25535366)
21. Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma.
Kfoury N; Qi Z; Prager BC; Wilkinson MN; Broestl L; Berrett KC; Moudgil A; Sankararaman S; Chen X; Gertz J; Rich JN; Mitra RD; Rubin JB
Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33850013
[TBL] [Abstract][Full Text] [Related]
22. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
23. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
Kodama M; Kodama T; Newberg JY; Katayama H; Kobayashi M; Hanash SM; Yoshihara K; Wei Z; Tien JC; Rangel R; Hashimoto K; Mabuchi S; Sawada K; Kimura T; Copeland NG; Jenkins NA
Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7301-E7310. PubMed ID: 28811376
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer.
Gao X; Wu X; Zhang X; Hua W; Zhang Y; Maimaiti Y; Gao Z; Zhang Y
Biochem Biophys Res Commun; 2016 Jan; 469(3):679-85. PubMed ID: 26707881
[TBL] [Abstract][Full Text] [Related]
25. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.
Zhang X; Liu P; Zhang B; Mao H; Shen L; Ma Y
Int J Mol Med; 2013 Sep; 32(3):623-8. PubMed ID: 23828376
[TBL] [Abstract][Full Text] [Related]
27. Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma.
Markman RL; Webber LP; Nascimento Filho CHV; Reis LA; Vargas PA; Lopes MA; Zanella V; Martins MD; Squarize CH; Castilho RM
Cell Oncol (Dordr); 2019 Apr; 42(2):143-155. PubMed ID: 30539410
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
29. Human amniotic epithelial cells inhibit growth of epithelial ovarian cancer cells via TGF‑β1-mediated cell cycle arrest.
Bu S; Zhang Q; Wang Q; Lai D
Int J Oncol; 2017 Nov; 51(5):1405-1414. PubMed ID: 29048644
[TBL] [Abstract][Full Text] [Related]
30. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of BRD4 Suppresses Cell Proliferation and Induces Apoptosis in Renal Cell Carcinoma.
Wu X; Liu D; Gao X; Xie F; Tao D; Xiao X; Wang L; Jiang G; Zeng F
Cell Physiol Biochem; 2017; 41(5):1947-1956. PubMed ID: 28391274
[TBL] [Abstract][Full Text] [Related]
32. Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.
Zhang L; Zhou D; Guan W; Ren W; Sun W; Shi J; Lin Q; Zhang J; Qiao T; Ye Y; Wu Y; Zhang Y; Zuo X; Connor KL; Xu G
Cell Death Dis; 2017 Dec; 8(12):3214. PubMed ID: 29238081
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
[TBL] [Abstract][Full Text] [Related]
34. AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo.
Xu K; Chen D; Qian D; Zhang S; Zhang Y; Guo S; Ma Z; Wang S
Biochem Biophys Res Commun; 2018 May; 499(3):531-537. PubMed ID: 29596834
[TBL] [Abstract][Full Text] [Related]
35. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
Ambrosini G; Sawle AD; Musi E; Schwartz GK
Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
[TBL] [Abstract][Full Text] [Related]
36. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-145 function as a cell growth repressor by directly targeting c-Myc in human ovarian cancer.
Zhang W; Wang Q; Yu M; Wu N; Wang H
Technol Cancer Res Treat; 2014 Apr; 13(2):161-8. PubMed ID: 23919393
[TBL] [Abstract][Full Text] [Related]
38. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.
Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA
Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834
[TBL] [Abstract][Full Text] [Related]
39. Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1.
Decker TM; Kluge M; Krebs S; Shah N; Blum H; Friedel CC; Eick D
Sci Rep; 2017 May; 7(1):1684. PubMed ID: 28490802
[TBL] [Abstract][Full Text] [Related]
40. [Effect of S1PR2 inhibition on epithelial ovarian cancer SKOV3 cell proliferation in vitro and in vivo].
Dai L; Liu YX; Xie L; Di W
Zhonghua Fu Chan Ke Za Zhi; 2018 Feb; 53(2):106-110. PubMed ID: 29534379
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
